W
WAVEMAN · COMPANY
RARE · Ultragenyx Pharmaceutical Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

RARE

Ultragenyx Pharmaceutical Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001515673
CONGRESS · 1FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$974.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
174
13F, latest reported quarter
REVENUE GROWTH
+20.2%
XBRL, annual
NET MARGIN
-85.4%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$974.6K over 180 days
-$416.9K over 90 days
below 60% of Pharma & Biotech
CONGRESS
1 member bought in the last year
the lowest in Pharma & Biotech
FUNDS
174 funds added or opened last quarter
more than 83% of Pharma & Biotech
REVENUE
+20.2% year over year
more than 69% of Pharma & Biotech
MARGIN
-85.4% net margin
below 63% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$974.6K across 5 people in 180 days.
174 funds added or opened positions in the latest 13F quarter, of 312 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -52.2%
-52.2%12M
-54%-31%-8%+14%2025-092025-102025-122026-032026-052026-072026-09 2026-03-02 · KAKKIS EMIL D sold $1.2M2025-10-13 · Horn Howard sold $250.3K2026-03-02 · Harris Erik sold $240.3K2026-03-02 · Pinion John Richard sold $228.7K2026-03-02 · Parschauer Karah Herdman sold $185.5K2026-03-02 · Crombez Eric sold $160.3K2026-07-01 · Horn Howard sold $155.6K2026-05-18 · SULIMAN SHEHNAAZ sold $144.2K2026-03-06 · Parschauer Karah Herdman sold $128.8K2026-03-02 · Horn Howard sold $120.6K2026-08-03 · Horn Howard sold $117.0K2026-05-01 · Horn Howard sold $116.6K2025-12-10 · Horn Howard sold $112.1K2026-06-01 · Horn Howard sold $110.6K2026-04-01 · Horn Howard sold $98.2K2026-03-10 · Parschauer Karah Herdman sold $79.5K2025-09-12 · Parschauer Karah Herdman sold $76.4K2026-02-02 · Horn Howard sold $72.1K2026-01-02 · Horn Howard sold $71.9K2026-03-02 · Horn Howard sold $70.3K2026-06-15 · Sanders Corazon (Corsee) D. sold $50.1K2026-08-03 · Parschauer Karah Herdman sold $47.3K2026-06-15 · Parschauer Karah Herdman sold $46.8K2026-03-02 · Huizenga Theodore Alan sold $37.2K2026-03-03 · Horn Howard sold $36.6K2026-05-05 · Crombez Eric sold $8.6K2025-12-29 · Huizenga Theodore Alan sold $2.9K2025-09-05 · Huizenga Theodore Alan sold $2.6K2025-09-18 · Huizenga Theodore Alan sold $1.9K2026-08-03 · HOWARD HORN filed to sell $117.0K2026-07-01 · HOWARD HORN filed to sell $155.6K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $974.6K sold by insiders over 180 days, 174 funds added last quarter, 1 Congress member(s) bought in 12 months, $272.7K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Ultragenyx Pharmaceutical Inc. insiders sold a net $974.6K of stock across 117 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Horn Howard
Chief Financial Officer
SELL
2026-08-03
4,696.0
$117.0K
Parschauer Karah Herdman
EVP and Chief Legal Officer
SELL
2026-08-03
1,900.0
$47.3K
Horn Howard
Chief Financial Officer
SELL
2026-07-01
4,698.0
$155.6K
Sanders Corazon (Corsee) D.
Director
SELL
2026-06-15
2,000.0
$50.1K
Parschauer Karah Herdman
EVP and Chief Legal Officer
SELL
2026-06-15
1,899.0
$46.8K
117 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 112 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
10,654,276.0 sh
$355.7M
RTW INVESTMENTS, LP
7,796,895.0 sh
$260.3M
VANGUARD PORTFOLIO MANAGEMENT LLC
6,790,135.0 sh
$226.7M
AQR CAPITAL MANAGEMENT LLC
6,560,809.0 sh
$214.1M
STATE STREET CORP
6,158,766.0 sh
$205.6M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
HOWARD HORN
FILED 2026-08-03
$117.0K
HOWARD HORN
FILED 2026-07-01
$155.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Motley Fool Small-Cap Growth ETF
$2.0M POSITION · AS OF 2026-02-28
2.8%
Global X Genomics & Biotechnology ETF
$930.4K POSITION · AS OF 2026-02-28
1.8%
AMG Frontier Small Cap Growth Fund
$1.5M POSITION · AS OF 2026-04-30
1.5%
Harbor Human Capital Factor US Small Cap ETF
$2.1M POSITION · AS OF 2026-04-30
1.3%
Virtus Biotech Etf
$644.9K POSITION · AS OF 2026-04-30
1.1%
AMG GW&K Small/Mid Cap Growth Fund
$428.0K POSITION · AS OF 2026-04-30
1.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 34 registered trials, 18 still enrolling or running — a status change here is dated weeks before the press release
5
Phase 2
1 ACTIVE
9
Phase 3
7 ACTIVE
12
Not applicable
6 ACTIVE
8
Multi-phase
4 ACTIVE
What changed recently
First-in-human Study of UX016 in GNEM
2026-09-04 · Not Yet Recruiting → Recruiting
PHASE1,PHASE2
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Ultragenyx Pharmaceutical Inc. Political Action Committee (Aka Ultragenyx Pac)
CYCLE 2026 · $62K SPENT
$49.0K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · Dr. Kakkis
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$11.4M
-$1.3M
$3.8M
-83%
+20%
2024
$13.7M
$8.2M
$4.3M
-70%
-9%
2023
$13.1M
$11.3M
$4.5M
-65%
-8%
2022
$12.1M
$3.3M
$3.9M
-67%
-11%
2021
$9.5M
-$2.2M
$3.3M
-39%
-1%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$673.0M$560.0M$434.0M$363.3M
OPERATING INCOME$-535.0M$-536.0M$-569.0M$-648.9M
NET INCOME$-575.0M$-569.0M$-607.0M$-707.4M
EPS (DILUTED)-5.83-6.29-8.25-10.12
OPERATING CASH FLOW$-466.0M$-414.0M$-475.0M$-380.5M
CASH$421.0M$174.0M$214.0M$132.9M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →